Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

There’s little doubt that losing evobrutinib is a heavy blow, given that Merck had been predicting sales of the drug could top $1 billion ... of launching a new product every 18 months.

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

(MRK) said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda in combination with pemetrexed and platinum chemotherapy as a first-line treatment for ...